• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上颌骨同时发生口腔鳞状细胞癌与双膦酸盐相关骨坏死:一例报告及文献综述

Concurrent Oral Squamous Cell Carcinoma and Bisphosphonate-Related Osteonecrosis of the Maxilla: A Case Report and Literature Review.

作者信息

Yoon Michelle, Ramirez Ricardo, Yun Jun, Wiedmer Christina, Brandwein-Weber Margaret, Khorsandi Azita S, Buchbinder Daniel, Khan Mohemmed N

机构信息

Thyroid, Head and Neck Cancer (THANC) Foundation, New York, New York, USA.

Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

出版信息

Head Neck. 2025 Jan;47(1):E1-E10. doi: 10.1002/hed.27974. Epub 2024 Oct 28.

DOI:10.1002/hed.27974
PMID:39463136
Abstract

INTRODUCTION

Bisphosphonates (BPs) are widely used for osteoporosis and cancer-induced bone diseases due to their antiresorptive properties, yet they pose risks such as medication-related osteonecrosis of the jaw (MRONJ).

METHODS

We present a unique case of concurrent oral squamous cell carcinoma (SCC) and MRONJ in a 72-year-old female chronically treated with oral ibandronate for osteoporosis. Following a dental extraction, she developed a nonhealing wound in the maxilla. Following conservative treatment, the patient underwent a maxillectomy and extensive tissue reconstructions to control her infection and address suspicions of an underlying malignancy.

RESULTS

Histopathological examinations confirmed simultaneous osteonecrosis and well-differentiated SCC in the maxillary sinus and surrounding tissues. Despite multiple surgeries, the patient's disease progressed rapidly. Upon examining the literature for patients with a history of BP use diagnosed with MRONJ and/or SCC, a total of 16 cases report a diagnostic dilemma between MRONJ and locoregional SCC. Three of the 16 cases report a final diagnosis of concurrent MRONJ and SCC. This report is the fourth reported case of concurrency to date.

CONCLUSIONS

The patient's complex clinical course underscores the diagnostic challenges and therapeutic dilemmas in managing concurrent MRONJ and SCC, highlighting the need for vigilant monitoring and interdisciplinary collaboration in similar cases.

摘要

引言

双膦酸盐(BPs)因其抗吸收特性而被广泛用于治疗骨质疏松症和癌症引起的骨疾病,但它们也带来了诸如药物相关性颌骨坏死(MRONJ)等风险。

方法

我们报告了一例独特的病例,一名72岁女性长期口服伊班膦酸钠治疗骨质疏松症,同时患有口腔鳞状细胞癌(SCC)和MRONJ。拔牙后,她上颌出现了不愈合的伤口。经过保守治疗后,患者接受了上颌骨切除术和广泛的组织重建,以控制感染并排除潜在恶性肿瘤的怀疑。

结果

组织病理学检查证实上颌窦及周围组织同时存在骨坏死和高分化SCC。尽管进行了多次手术,患者的病情仍迅速进展。在查阅有BP使用史且被诊断为MRONJ和/或SCC的患者的文献时,共有16例报告了MRONJ和局部SCC之间的诊断困境。16例中有3例最终诊断为MRONJ和SCC并发。本报告是迄今为止第四例并发病例报告。

结论

患者复杂的临床病程凸显了在处理MRONJ和SCC并发时的诊断挑战和治疗困境,强调了在类似病例中进行密切监测和跨学科协作的必要性。

相似文献

1
Concurrent Oral Squamous Cell Carcinoma and Bisphosphonate-Related Osteonecrosis of the Maxilla: A Case Report and Literature Review.上颌骨同时发生口腔鳞状细胞癌与双膦酸盐相关骨坏死:一例报告及文献综述
Head Neck. 2025 Jan;47(1):E1-E10. doi: 10.1002/hed.27974. Epub 2024 Oct 28.
2
Interventions for managing medication-related osteonecrosis of the jaw.颌骨药物相关性骨坏死的管理干预措施。
Cochrane Database Syst Rev. 2017 Oct 6;10(10):CD012432. doi: 10.1002/14651858.CD012432.pub2.
3
Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.每年一次静脉输注唑来膦酸治疗骨质疏松症后发生的药物相关性颌骨坏死:8例报告
Quintessence Int. 2016;47(5):433-40. doi: 10.3290/j.qi.a35263.
4
Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.药物相关性颌骨坏死:双膦酸盐治疗患者与抗吸收-抗血管生成药物治疗患者的风险因素
Minerva Stomatol. 2017 Aug;66(4):135-140. doi: 10.23736/S0026-4970.17.04056-0. Epub 2017 May 10.
5
[Position paper on medication-related osteonecrosis of the jaw (MRONJ)].[关于药物性颌骨坏死(MRONJ)的立场文件]
Wien Med Wochenschr. 2016 Feb;166(1-2):68-74. doi: 10.1007/s10354-016-0437-2.
6
[Therapeutic alternatives for drug-associated maxillary osteonecrosis (MRONJ): reports of two clinical cases and review of the literature].[药物相关性上颌骨坏死(MRONJ)的治疗选择:两例临床病例报告及文献综述]
Rev Fac Cien Med Univ Nac Cordoba. 2022 Dec 21;79(4):379-382. doi: 10.31053/1853.0605.v79.n4.37289.
7
Interventions for managing medication-related osteonecrosis of the jaw.干预措施管理与药物相关的颌骨坏死。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD012432. doi: 10.1002/14651858.CD012432.pub3.
8
A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?一项多中心回顾性研究,探讨了接受口服双膦酸盐治疗的拔牙后药物相关性颌骨坏死的相关风险因素:原发伤口闭合和药物暂停真的能预防 MRONJ 吗?
Osteoporos Int. 2017 Aug;28(8):2465-2473. doi: 10.1007/s00198-017-4063-7. Epub 2017 Apr 27.
9
"Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review."自发性"药物相关性下颌骨坏死;两例报告和系统评价。
Aust Dent J. 2018 Dec;63(4):441-454. doi: 10.1111/adj.12648. Epub 2018 Sep 9.
10
The Prevention of Medication-related Osteonecrosis of the Jaw.预防药物相关性颌骨坏死。
Dtsch Arztebl Int. 2017 Feb 3;114(5):63-69. doi: 10.3238/arztebl.2017.0063.

引用本文的文献

1
Oral squamous cell carcinoma vs. medication-related osteonecrosis of the jaw in patients assuming bone-modifying agents: a diagnostic challenge in a multi-hospital case series.服用骨改良剂患者的口腔鳞状细胞癌与药物相关性颌骨坏死:多医院病例系列中的诊断挑战
Front Oral Health. 2025 Jun 12;6:1574425. doi: 10.3389/froh.2025.1574425. eCollection 2025.